Program
BCD-248
A development code. Also written as “BCD-248 + daratumumab”.
Its studies are mostly in Multiple Myeloma, led by Biocad.
Furthest: phase 3, since Jul 23, 20262 company-led studies, 2 open or runningNext primary completion: Jul 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biocad | 22 open or running | phase 3since Jul 23, 2026 | Oct 30, 2024 | Jul 2028phase 3 · NCT07742215 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 30, 2024First study: phase 2 study in Multiple MyelomaFirst studyNCT06668792 · 100 planned · Russian Federation
- Jul 23, 2026Phase 3 study in Multiple MyelomaPhase 3 reachedNCT07742215 · 390 planned · Belarus, Russia
Ahead
- Jul 2028Primary completion: phase 3 study in Multiple MyelomaNCT07742215
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07742215Multiple Myeloma · Belarus, Russia | 3 | Recruiting | Jul 2028 | 390 |
| NCT06668792Multiple Myeloma · Russian Federation | 2 | Recruiting | Feb 2026 | 100 |
How it is read
Names in the registry
- “BCD-248 + daratumumab”, 1 entry
- “BCD-248”, 1 entry
Codes read as this program: BCD248.
Conditions, from the studies’ own filings
- Multiple Myeloma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.